MAP2K1 and neoplasm: One patient with advanced parotid adenocystic carcinoma, whose tumour had a mutation in HRAS remained on treatment with stable disease for 15 cycles; this is interesting in the context that HRAS has been proposed as a target for MEK1/2 inhibitors [55].